Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors
Tarek S. Ibrahim, Azizah M. Malebari, Mamdouh F. A. Mohamed
Pharmaceuticals (2021) Vol. 14, Iss. 11, pp. 1177-1177
Open Access | Times Cited: 15

Showing 15 citing articles:

Synthesis and physicochemical properties of an aromatic chitosan derivative: In vitro antibacterial, antioxidant, and anticancer evaluations, and in silico studies
Tamer M. Tamer, Hongyan Zhou, Mohamed A. Hassan, et al.
International Journal of Biological Macromolecules (2023) Vol. 240, pp. 124339-124339
Closed Access | Times Cited: 29
Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors
G. Sivaiah, M.S. Raghu, S. Prasad, et al.
Journal of Molecular Structure (2024) Vol. 1309, pp. 138223-138223
Closed Access | Times Cited: 11
Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities
Asmaa Ahmed, Mamdouh F. A. Mohamed, Rasha M. Allam, et al.
Bioorganic Chemistry (2022) Vol. 129, pp. 106171-106171
Closed Access | Times Cited: 28
Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 5
Closed Access | Times Cited: 4
Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents
Eman A. Ahmed, Mamdouh F. A. Mohamed, Omran A. Omran
RSC Advances (2022) Vol. 12, Iss. 39, pp. 25204-25216
Open Access | Times Cited: 20
Design, synthesis and antitumor evaluation of novel pyrazolo[3,4- d ]pyrimidines incorporating different amino acid conjugates as potential DHFR inhibitors
Ibrahim M. Salem, Samia M. Mostafa, Ismail Salama, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 38, Iss. 1, pp. 203-215
Open Access | Times Cited: 17
Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review
Chao Wang, Yujing Zhang, Tingting Zhang, et al.
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127440-127440
Closed Access | Times Cited: 8
Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency
Yuan Jiang Pan, Haodong Hou, Bo Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115879-115879
Closed Access | Times Cited: 8
Recent developments of hydroxamic acid hybrids as potential anti-breast cancer agents
Xinran Cao, Yufeng Gong
Future Medicinal Chemistry (2024) Vol. 16, Iss. 5, pp. 469-492
Open Access | Times Cited: 2
Exploring the antimicrobial and cytotoxic potential of novel chloroquine analogues
Shamsul Islam, Sohail Anjum Shahzad, Tariq Ismail, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 8, pp. 737-749
Closed Access | Times Cited: 1
Human dihydrofolate reductase inhibition effect of 1-Phenylpyrazolo[3,4–d]pyrimidines: Synthesis, antitumor evaluation and molecular modeling study
Ibrahim M. Salem, Samia M. Mostafa, Ismail Salama, et al.
Bioorganic Chemistry (2022) Vol. 129, pp. 106207-106207
Closed Access | Times Cited: 4
Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation
Chunhong Chu, Huixia Xu, Chenxue Liu, et al.
Current Research in Toxicology (2024) Vol. 7, pp. 100194-100194
Open Access
Special Issue “Anticancer Drugs 2021”
Mary J. Meegan, Niamh M. O’Boyle
Pharmaceuticals (2022) Vol. 15, Iss. 4, pp. 479-479
Open Access | Times Cited: 3
Design, Synthesis and Anticancer Evaluation of New 1-allyl-4-oxo-6-(3,4,5- trimethoxyphenyl)-1,4-dihydropyrimidine-5-carbonitrile Bearing Pyrazole Moieties
Nermine A. Osman, N S Khalaf and H M Hassan Ragab A El-Sayed, Hanan A. Abdel Fattah, et al.
Current Organic Synthesis (2023) Vol. 20, Iss. 8, pp. 897-909
Closed Access | Times Cited: 1
Recent review on selective histone deacetylase inhibitors in cancer therapy
Aya I. Abd El-hameed, Mamdouh F. A. Mohamed, Eman A. M. Beshr
Deleted Journal (2023)
Open Access
Page 1

Scroll to top